Violet Therapeutics, Inc.
Cambridge, US · 7 known investors
Find your way into Violet Therapeutics, Inc.
Violet is a therapeutics company developing small molecule treatments for central nervous system diseases, using its proprietary C-to-C Engine platform to identify disease-relevant cell-to-cell interactions. Its lead program is a small molecule inhibitor of EphB3, a receptor tyrosine kinase involved in microglia-astrocyte interactions linked to glial dysfunction in neurodegenerative disease.
Investors · 7
Dementia DiscoveryLondon
Ono Venture Investment, Inc.South San Francisco
SV Health InvestorsBoston · $1M – $20M
UTECTokyo · $3.1M – $78M
Dementia Discovery Fundreported · 2 sourcesLondon
Also in the syndicate · 2
Mass General Brigham Ventures (MGBV)UTEC (University of Tokyo Edge Capital Partners)lead
Funding
SEC filings, press & company announcements- Undisclosed amountseed funding roundMay 2023
Dementia Discovery Fund (lead), UTEC (University of Tokyo Edge Capital Partners) (lead), Mass General Brigham Ventures (MGBV), Ono Venture Investment
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Violet Therapeutics, Inc. do?
- Violet is a therapeutics company developing small molecule treatments for central nervous system diseases, using its proprietary C-to-C Engine platform to identify disease-relevant cell-to-cell interactions. Its lead program is a small molecule inhibitor of EphB3, a receptor tyrosine kinase involved in microglia-astrocyte interactions linked to glial dysfunction in neurodegenerative disease.
- Who are Violet Therapeutics, Inc.'s investors?
- Violet Therapeutics, Inc.'s investors include Dementia Discovery, Ono Venture Investment, Inc., SV Health Investors, UTEC, Dementia Discovery Fund.
- Where is Violet Therapeutics, Inc. headquartered?
- Violet Therapeutics, Inc. is headquartered in Cambridge, US.